Pre-clinical study proving chondrointegration accepted for publication in scientific journal
Episurf Medical (NASDAQ: EPIS B) today announces that a peer-reviewed article showing that chondrointegration of the Episealer® implant improves after hydroxyapatite coating has been accepted for publication in a scientific paper.
The publication with the title “Therapy of osteochondral defects: chondrointegration of metal implants improves after hydroxyapatite coating” by H. Schell et al. at Julius Wolff Institut, Charité University Hospital, Berlin, Germany, will be published in the journal Knee Surgery, Sports Traumatology, Arthroscopy and is shortly available online.
“The article is extremely exciting as the concept ”chondrointegration”, which is a unique feature of the Episealer® implant, becomes accepted in the field of cartilage surgery. In this comparative sheep study it has been shown that cartilage adheres to the hydroxyapatite which is used for coating of the Episealer® implant. This encourages sealing of the cartilage lesion, resulting in protection of the deeper parts of the joint from aggressive joint fluid, which, in turn, should give better longevity of the implant” says Prof. Leif Ryd, Senior Medical Advisor, Episurf Medical.
“This publication is very welcome for us, as high-quality peer-reviewed evidence is a must for orthopaedic surgeons in their treatment decisions” comments Pål Ryfors, CEO, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14.50 CET on 11 March 2019.